Atripla (Efavirenz/Tenofovir/FTC): News
 HIV Meds and False Positives on Drug Tests: A Video Blog by Aaron Laxton (February 11, 2013)
"If you're on [Atripla] and you're going to have to do a drug screen ... you need to let the tester know whenever they do your drug screen whatever medications you're on. ... It's not the end of the world, but it's definitely something you need to know about."
From TheBody.com
 Antiretroviral Rounds: Resistance on Two Fronts (November 2, 2012)
From Journal Watch
On TheBodyPRO.com
- Switching From Atripla to Complera (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Complera and Atripla News (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Gilead Raises Prices of HIV Drugs, AHF Speaks Out Against Price Hike (April 4, 2011)
In Bloomberg Businessweek
- Atripla's Co-Pay Program Now Saves More Money (September/October 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm? (Feb. 19, 2010; 3:39 p.m. Pacific Time)
A blog entry from CROI 2010 by Gerald Pierone Jr., M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Atripla Label Update Reflects New Efficacy, Safety and Resistance Data in Treatment Experienced Patients (January 7, 2010)
From U.S. Food and Drug Administration
- Australia: New HIV Drug Added to Taxpayer-Subsidized List (January 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Approval for Once-A-Day HIV Pill (December 17, 2007)
In BBC News Online, from BBC News
- FDA Approves Gilead, Bristol-Myers Squibb Once-a-Day Combination Antiretroviral Pill (July 13, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Single-Pill, Once-Daily HIV Drug Regimen Submitted for FDA Approval (April 28, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here.
From Bristol-Myers Squibb Company and Gilead Sciences, Inc.
- Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
|
Advertisement
|
Email
Glossary
